AT-1001 / INN-202
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
An oral eight-amino-acid tight-junction regulator (zonulin antagonist) intended to restore intestinal barrier function, often framed as a "leaky gut" peptide. It is the most clinically advanced compound in this space, having reached a Phase 3 trial for celiac disease – but that trial (CeDLara) missed its primary endpoint in 2022, so it is not approved and its benefit remains unproven. It is widely sold research-grade and folded into gut-repair blends, though there is no controlled evidence for the general gut-healing uses vendors promote.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published dose for this compound, shown as reference. Included with membership.
